Preclinical studies across various cancer types suggest that TREM2 is a promising therapeutic target for cancer immunotherapy.In non-small cell lung cancer (NSCLC), TREM2+ TAMs are enriched in immunologically “cold” tumors and correlate with poor response to anti–PD-1 therapy. The gene discussed is TREM2; the disease is cancer.